FDA wants Congress to create a safe harbor that protects generic drug makers from being held liable for patent infringement when they market a drug with a so-called skinny label -- that is, when a generic drug manufacturer’s product is approved and marketed for one or more off-patent uses of a brand drug, and only the off-patent uses are reflected in the drug’s label. The administration is proposing the legislation due to a federal appeals court decision last year that...